Fig. 4: Probing the mechanism of S2-based protection. | Nature Communications

Fig. 4: Probing the mechanism of S2-based protection.

From: Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice

Fig. 4

a Schedule for mouse pre-treatment with anti-CD8 antibody or PBS, immunization, infection with mouse-adapted SARS-CoV-2, and lung tissue collection. b Virus titers in the lungs of BALB/c mice immunized with VLP-CoV-1 S2 three days after mouse-adapted SARS-CoV-2 challenge (mean ± SD, n = 5 biological replicates for VLP-Control and S2 CD8(+) groups, n = 4 biological replicates for S2 CD8(-) group). ● indicate data from individual mice. The detection limit (dotted line) = 1.3 log10 pfu/g. The VLP-CoV-1 S2 CD8(+) group represents mice injected with PBS before the challenge, and the VLP-CoV-1 S2 CD8(-) group represents mice injected with CD8-depleting antibodies before the challenge. ****P < 0.0001, ns: not significant, determined by an ordinary one-way ANOVA and Tukey post hoc multiple comparisons between groups. c Virus titers in the lungs of mice immunized with VLP-CoV-1 S2 three days after MA10 challenge (mean ± SD, n = 5 biological replicates for wild-type BALB/c and n = 4 for FcγR KO). ● indicate data from individual mice. The detection limit (dotted line) = 1.3 log10 pfu/g. The FcγR KO group represents Fc-gamma receptor knocked out BALB/c mice. **P = 0.0031,****P < 0.0001, determined by two-tailed Welch’s t test.

Back to article page